Poziotinib
Poziotinib is a pharmaceutical drug with 11 clinical trials. Historical success rate of 50.0%.
Success Metrics
Based on 5 completed trials
Phase Distribution
Phase Distribution
2
Early Stage
8
Mid Stage
1
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
50.0%
5 of 10 finished
50.0%
5 ended early
0
trials recruiting
11
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Study of Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 20 Mutations
Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC
Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation
A Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to Poziotinib
Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)]
Clinical Trials (11)
A Study of Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 20 Mutations
Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC
Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation
A Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to Poziotinib
Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)]
Study of Poziotinib in Participants With HER2-Positive Metastatic Breast Cancer
A Study to Evaluate the Effect of Multiple Doses of Itraconazole, Phenytoin, and Paroxetine on the Single-Dose Pharmacokinetics of Poziotinib in Healthy Adult Participants
A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast Cancer
Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation
A Phase II, Single-Arm Trial of Poziotinib as Salvage Treatment in Patients With Metastatic Breast Cancer Who Has HER2 or EGFR Mutation or Activated AR or EGFR Pathway
Poziotinib in Stage IV Lung Adenocarcinoma With HER2 Mutation (KASTT001)
All 11 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 11